2018 Symposium on “Human Pluripotent Stem Cell-based Precision Medicine and Therapies for Heart Diseases: From Concepts to Realities”
The symposium was co-organised by MWLC and Dr. Li Dak-Sum Research Centre, HKU. It featured a full day programme on topics including cardiac regenerative medicine, novel bioengineering technologies, and translational bench to bedside regenerative medicine.
Session I: Cell-Based Cardiac Therapies
Gene therapy & genome editing for acquired and experimental heart failure
Roger Hajjar
Director, Cardiovascular Research Center
Arthur & Janet C. Ross Professor of Medicine, Icahn School of Medicine at Mount Sinai
The potential of human induced pluripotent stem cells to model and to treat congenital heart disease
Yiu-fai Cheung
Bryan Lin Professor in Paediatric Cardiology
Clinical Professor, Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong
Development of banking and testing protocols for GMP hiPSC
Jo Mountford
Head of Cellular Therapeutics, Tissues Cells and Advanced Therapies, Scottish National Blood Transfusion Service
Hon. Associate Professor, Institute of Cardiovascular and Medical Sciences, University of Glasgow
Predicting individual arrhythmogenic risk at the individual level using hiPSC
Jean-Sébastien Hulot
Team Leader, Clinical & Translational Investigation Center, Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest) Paris Cardiovascular Research Center PARCC / INSERM
Session II: Tissue Engineering and Drug Discovery
Engineering cardiac tissue and development
Peter Zandstra
Director, School of Biomedical Engineering, The University of British Columbia
A tissue-engineered scale model of the heart ventricle
Luke MacQueen/Kit Parker
Postdoctoral Fellow / Professor, Bioengineering in the Wyss Institute, Harvard University
Small molecule drug discovery, transitioning from industry to academia: SERCA2a SUMO activators for heart failure
Robert DeVita
Director of Medicinal Chemistry, Drug Discovery Institute
Professor, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Session III: Drug and Therapeutics Safety and Discovery in Industry
Stem cell cardiomyocytes in drug discovery and development – are we there yet?
Bernard Fermini
Co-Chair, CiPA Ion Channel Working Group of the U.S. Food and Drug Administration
New challenges in safety pharmacology
Sonja Stoelzle-Feix
Director Scientific Affairs at Nanion Technologies
Co-chair, CiPA Ion Channel Working Group of the U.S. Food and Drug Administration
Toward a precision medicine approach to drug screening using Novoheart’s hPSC-based MyHeartTM Platform
Kevin Costa
Co-founder and Chief Scientific Officer, Novoheart
Collaborating to create engineered human tissues using 3D bioprinting technology
Tamer Mohamed
President and Chief Executive Officer, Aspect Biosystems
Session IV: Commercializing Regenerative Medicine and Therapeutics
Scale-up of pluripotent stem cell production to enable translation and commercialization
Emily Titus
Vice President, Technology Advancement, Centre for Commercialization of Regenerative Medicine (CCRM)
Where is Hong Kong in developing precision medicine?
Sabrina Chan
Senior Executive Director, The Hong Kong Association of the Pharmaceutical Industry
